clinical trials, data, drug development, ema, market access, patients, Real World Evidence, regulation, RWE
0 Comment
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
2016, breakthrough, cancer, clinical trial, ESMO, immuno-oncology, immunotherapy, Oncology, patients, quintilesIMS, treatment
0 Comment
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
breakthrough, cancer, clinical trial, development, ESMO, immuno-oncology, pipeline, quintilesIMS, treatment
0 Comment
cancer, immuno-oncology, immunotherapy, pharma, quintiles, webinar
0 Comment
In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
